Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4Withdrawn 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × ofatumumab × Clear all
NCT00092274 2015-04-21

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

GlaxoSmithKline

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00093314 2015-04-21

HuMax-CD20 in Chronic Lymphocytic Leukemia

GlaxoSmithKline

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡